http://www.phlebolymphology.org/wp-content/pdf/Phlebolymphology43.pdf

Read pages 213-216.



Micronization offers improved efficacy in CVI
By acting at the heart of CVI, daflon 500 mg is effective at all
stages of disease. However, flavonoids have a poor gastrointestinal
absorption. This is overcome, in daflon 500 mg’s case,
by the process of micronization: a high-tech process which
reduces daflon 500 mg’s mean active particle size by 35 µm
with a subsequent faster and better absorption in humans with improved bioavailability. This has been conclusively
demonstrated in a single-center, randomized, double-blind,
crossover study in 12 healthy male volunteers. Immediately
from 24 hours postingestion, daflon 500 mg’s absorption
(measured by urinary radioactivity) is almost twice that of
simple diosmins (P<0.0001). This improved absorption of
daflon 500 mg over simple diosmins is maintained after 2
weeks of treatment (57.9% vs 32.7%; P<0.0004).7 Therefore,
evidence that, thanks to micronization, daflon 500 mg’s
absorption is almost doubled, leading to significantly
improved clinical efficacy.